Up to 60 millions doses of the AstraZeneca vaccine will be shared once it clears federal safety reviews.
Health advisers declared Wednesday that they need more evidence to decide if a handful of unusual blood clots were linked to the shot.
AstraZeneca walked back its claim on how effective its COVID-19 vaccine was after top public health officials alleged the company used incomplete data from clinical trials.
The company drew fire for the alleged exclusion of some cases of COVID-19 in clinical trial participants.
Results from a U.S. trial of the vaccine may have used "outdated information," U.S. federal health officials said.
The shot was found 100% effective at preventing severe COVID-19, in early findings to be submitted to the Food and Drug Administration.
The other is in serious condition.
With the nation now administering about 2.5 million shots per day, the U.S. cleared Biden's goal of 100 million coronavirus vaccine shots a month early.
The shot is linked to reports of blood clots and lower efficacy against COVID-19 variants, but there's more that everyone needs to understand.
“I’m proud to announce that tomorrow, 58 days into our administration, we will have met our goal,” the president said Thursday.